Myeloproliferative Neoplasms
This novel JAK2 inhibitor features reduced off-target suppression of JAK1, JAK3, TYK2, and other kinases.
Detailed findings from SURPASS-ET including pharmacokinetic and biomarker data will be presented in the future.
Efficacy and safety primary analysis findings are reported from the international, open-label FREEDOM2 trial.
Initial findings from a phase I study show the compound significantly reduces the need for phlebotomy in patients with PV.
Study identifies risks of thrombosis, hemorrhage, and leukemic transformation in patients with myelofibrosis and other MPNs.
Momelotinib and ruxolitinib improved bone marrow fibrosis, but changes were not associated with improved outcomes in MF.
Splenic radiation effectively managed splenomegaly before HSCT for myelofibrosis and significantly reduced relapse afterward.
Dr. Grunwald of the Atrium Health Levine Cancer Institute, discusses caring for patients with PV on rare disease day.
The study evaluated the impact of mutations on the risk of thromboembolic events, disease progression, and patient mortality.
Fedratinib induced superior spleen volume and symptom response versus best available therapy in patients with myelofibrosis.
Advertisement
Expert Interviews on Hematology
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.